In a move to diversify its investment portfolio, 21 Invest, led by Alessandro Benetton, has launched a healthcare fund.
The fund has completed its first closing, raising 70 million euros, with a target of 150 million euros. The fund is classified as an Article 9 fund under the European Sustainable Finance Disclosure Regulation (SFDR), emphasizing its commitment to impact investing. The focus will be on Italian and European companies that are innovating in products and services aimed at enhancing wellbeing.
The fund will target investments in healthcare, wellness, and wellbeing, with a particular emphasis on nutraceuticals, advanced cosmetics, and veterinary services. The average investment per transaction is expected to range between 10 and 15 million euros.
To strengthen its healthcare investment strategy, 21 Invest has assembled a specialized team with extensive experience in private equity within the medical sector. The team includes partners Stefania Petruccioli, Alessandro Damiano, and Fabio Parisi, along with principal Michele Fodde. The broader 21 Invest group has a workforce of over 50 professionals spread across Italy, France, and Poland.
This initiative is not 21 Invest's first venture into the medical and pharmaceutical fields. The group has previously collaborated with companies such as France's Plg and the Italian company Sifi. These experiences have equipped 21 Invest with valuable insights and connections that will be instrumental in the success of the new healthcare fund.
Alessandro Benetton, chairman and founder of 21 Invest, expressed that this fund represents a significant contribution to a vital area of society. The focus on innovative products and services reflects a growing trend among investors to seek opportunities that contribute to the greater good.
The establishment of the 21 Invest Healthcare fund comes at a time when the European investment landscape is becoming increasingly competitive. With a growing emphasis on sustainability and impact investing, funds that align with these principles are likely to attract significant interest from both institutional and retail investors. The support from established entities such as the Italian Fund and the European Investment Fund underscores the confidence in 21 Invest's approach and the potential for success in this sector.
Moreover, the healthcare industry is experiencing a surge in demand for innovative solutions, particularly in light of recent global health challenges. This environment presents a unique opportunity for investors to capitalize on emerging trends while contributing to advancements in healthcare. The focus on sectors such as nutraceuticals and advanced cosmetics indicates a forward-thinking strategy that aligns with consumer preferences for health-oriented products.
As 21 Invest embarks on this new venture, the combination of a specialized team, strategic partnerships, and a clear focus on impact investing positions the healthcare fund as a noteworthy player in the evolving investment landscape. The commitment to enhancing wellbeing through innovative solutions not only reflects a sound investment strategy but also addresses pressing societal needs, making it a timely and relevant initiative in today's market.